Here's Why Galectin Therapeutics (GALT) Is Poised for a Turnaround After Losing -31.83% in 4 Weeks
Catalyst Watch: November Jobs, OPEC+ Meeting, Marvell, Salesforce Earnings
Galectin Therapeutics Presents Clinical Data on NAVIGATE Trial for Esophageal Varices in MASH Cirrhosis at AASLD 2024
Galectin Therapeutics Presents 3 Abstracts At The American Association For The Study Of Liver Diseases 2024 Liver Meeting
Earnings Week Ahead: NVDA, WMT, SNOW, TGT, BIDU, NIO, ZIM, and More
H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11
